Sunshine Biopharma Finalizes $6M Unit Offering at $0.55 — 43.6M Warrant Shares Loom
SBFM is trading near its 52-week low of $0.331 (3.2% below the low).
Summary
Sunshine Biopharma finalized a $6 million best-efforts unit offering at $0.55 per unit, with each unit carrying two Series D Warrants that could add up to 43.6 million shares. Net proceeds of ~$5.2 million fund working capital, but the warrant overhang is massive relative to the 4.3 million shares currently outstanding. The offering closed on October 9, 2026, with gross proceeds of approximately $6 million.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The offering closed on October 9, 2026, with gross proceeds of approximately $6 million.
Key Events · Financing and Capital Events · SBFM
-
Updated · · SEC 8-K
$6M Unit Offering Finalized and Closed
Up to 10,509,082 Common Units at $0.55 each, each with one share and two Series D Warrants, plus up to 400,000 Pre-Funded Units. Total gross proceeds capped at $6 million. The offering closed on October 9, 2026, with gross proceeds of approximately $6 million.
-
Massive Warrant Overhang
21,818,164 Series D Warrants exercisable at $0.66 for five years, plus 400,000 Pre-Funded Warrants at $0.00001. If fully exercised, up to 43.6 million new shares — over 10x the current 4.3 million outstanding.
-
Share Combination Event Reset
Series D Warrants include a provision that can reduce the exercise price to as low as $0.275 (50% of offering price) if a reverse split occurs and the VWAP falls below the exercise price, subject to stockholder approval.
-
Net Proceeds ~$5.2M
After 7% placement agent fee ($420K), 1% non-accountable expense allowance, and ~$340K in other expenses. Proceeds for general corporate purposes and working capital.
Analysis · SBFM · Life Sciences
Sunshine Biopharma has finalized terms for a best-efforts offering that will raise approximately $5.2 million in net proceeds, but the structure is highly dilutive. Each $0.55 Common Unit includes two Series D Warrants exercisable at $0.66, meaning up to 43.6 million additional shares could eventually hit the market — more than ten times the current 4.3 million shares outstanding. The offering price of $0.55 sits well above today's $0.3205 trading price, but the filing's own reference price of $0.34 (last sale on October 9) shows the deal was priced at a premium to the market at the time of pricing. The company is trading near its 52-week low and faces Nasdaq delisting risk, with a reverse split approved but not yet effective. This capital raise is survival financing, but the warrant overhang and the Share Combination Event provision — which can reset the exercise price down to $0.275 — create substantial future dilution risk for existing holders. The offering closed on October 9, 2026, with gross proceeds of approximately $6 million.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.33 to $24.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.